NPM1 and acute myeloid leukemia: We validated these clinical and molecular findings in an independent validation cohort of 302 <i>NPM1</i> <sup>mut</sup> patients enrolled in the acute myeloid leukemia study group (AMLSG) 09-09 clinical trial, which included the administration of all-trans retinoic acid (ATRA) to all patients and a randomization for gemtuzumab ozogamicin.